Guardant Stock Analysis

GH
 Stock
  

USD 49.50  2.91  5.55%   

The modest gains experienced by current holders of Guardant Health may raise some interest from stockholders. The stock closed today at a share price of 49.50 on 463,669 in trading volume. The company directors and management have been quite successful in maneuvering the stock at opportune times to take advantage of all market conditions in November. The stock standard deviation of daily returns for 90 days investing horizon is currently 5.19. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Guardant Health partners.
Please check Risk vs Return Analysis.
  
The Guardant Health stock analysis report makes it easy to digest most publicly released information about Guardant Health and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Guardant Stock analysis module also helps to analyze the Guardant Health price relationship with some important fundamental indicators such as market cap and management efficiency.

Guardant Stock Analysis Notes

About 95.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 4.13. Guardant Health had not issued any dividends in recent years. Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company was incorporated in 2011 and is headquartered in Redwood City, California. Guardant Health operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 1373 people. To learn more about Guardant Health call Helmy Eltoukhy at 855 698 8887 or check out https://guardanthealth.com.

Guardant Health Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Guardant Health's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Guardant Health or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Guardant Health has very high historical volatility over the last 90 days
The company generated the yearly revenue of 373.65 M. Annual Net Loss to common stockholders was (405.67 M) with gross profit of 250.74 M.
Guardant Health reports about 853.69 M in cash with (209.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.35.
Guardant Health has a frail financial position based on the latest SEC disclosures
Over 95.0% of the company shares are owned by institutional investors
Latest headline from news.google.com: Guardant Health Rich Implied Volatility Broken Wing Butterflies - Seeking Alpha

Guardant Health Upcoming and Recent Events

Earnings reports are used by Guardant Health to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Guardant Health previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report23rd of February 2022
Next Financial Report5th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End23rd of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Guardant Largest EPS Surprises

Earnings surprises can significantly impact Guardant Health's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2020-02-24
2019-12-31-0.31-0.270.0412 
2019-03-12
2018-12-31-0.35-0.30.0514 
2019-05-09
2019-03-31-0.37-0.30.0718 
View All Earnings Estimates

Guardant Health SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Guardant Health prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Guardant Health investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Guardant Health specific information freely available to individual and institutional investors to make a timely investment decision.
4th of August 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
7th of July 2022
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
21st of June 2022
Submission of Matters to a Vote of Security Holders
View
13th of June 2022
Financial Statements and Exhibits. Other Events. Termination of a Material Definitive Agreement
View
5th of May 2022
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Results of Operations and Financial Condition
View
9th of March 2022
Unclassified Corporate Event
View
28th of February 2022
Other Events. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
23rd of February 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View

Guardant Market Capitalization

The company currently falls under 'Mid-Cap' category with market capitalization of 5.36 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Guardant Health's market, we take the total number of its shares issued and multiply it by Guardant Health's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Guardant Profitablity

Guardant Health's profitability indicators refer to fundamental financial ratios that showcase Guardant Health's ability to generate income relative to its revenue or operating costs. If, let's say, Guardant Health is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Guardant Health's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Guardant Health's profitability requires more research than a typical breakdown of Guardant Health's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Net Profit Margin (PM) of (1.41) %, which may indicate that it does not properly execute on its own pricing strategies. This is way below average. Likewise, it shows Net Operating Margin (NOM) of (1.15) %, which signifies that for every 100 dollars of sales, it has a net operating loss of -0.01.
Last ReportedProjected for 2022
Return on Investment(21.16) (22.83) 
Return on Average Assets(18.13) (19.56) 
Return on Average Equity(41.75) (45.04) 
Return on Invested Capital(0.15) (0.16) 
Return on Sales(1.08) (1.16) 

Management Efficiency

The entity has Return on Asset (ROA) of (0.1573) % which means that for every 100 dollars spent on asset, it generated loss of $0.1573. This is way below average. Likewise, it shows return on total equity (ROE) of (1.2548) %, which implies that it produced no returns to current stockholders. Guardant Health management efficiency ratios could be used to measure how well guardant health manages its routine affairs as well as how well it operates its assets and liabilities. The current Return on Investment is estimated to decrease to -22.83. The current Return on Average Assets is estimated to decrease to -19.56. Guardant Health Goodwill and Intangible Assets are most likely to increase significantly in the upcoming years. The last year's value of Goodwill and Intangible Assets was reported at 17.5 Million. The current Revenue to Assets is estimated to increase to 0.19, while Current Assets are projected to decrease to roughly 896.2 M.
Last ReportedProjected for 2022
Book Value per Share 6.37  8.61 
Enterprise Value over EBIT(27.00) (29.13) 
Enterprise Value over EBITDA(30.03) (32.40) 
Price to Book Value 15.76  14.31 
Tangible Assets Book Value per Share 21.59  21.95 
Enterprise Value10.7 B10.5 B
Tangible Asset Value2.2 B1.8 B

Technical Drivers

As of the 2nd of December, Guardant Health retains the risk adjusted performance of 0.0813, and Market Risk Adjusted Performance of 0.124. Guardant Health technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We have analyze and collected data for nineteen technical drivers for Guardant Health, which can be compared to its competitors. Please check out Guardant Health jensen alpha, semi variance, and the relationship between the standard deviation and value at risk to decide if Guardant Health is priced fairly, providing market reflects its last-minute price of 49.5 per share. Given that Guardant Health has jensen alpha of 0.0022, we strongly advise you to confirm Guardant Health's regular market performance to make sure the company can sustain itself at a future point.

Guardant Health Price Movement Analysis

The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Triangular Moving Average shows Guardant Health double smoothed mean price over a specified number of previous prices (i.e., averaged twice).
.

Guardant Health Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Guardant Health insiders, such as employees or executives, is commonly permitted as long as it does not rely on Guardant Health's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Guardant Health insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Joyce Meghan V over a month ago via Macroaxis 
Exercise or conversion by Joyce Meghan V of tradable shares of Guardant Health subject to Rule 16b-3
Eagle Craig over two months ago via Macroaxis 
Exercise or conversion by Eagle Craig of 3717 shares of Guardant Health subject to Rule 16b-3
Joyce Meghan V over two months ago via Macroaxis 
Exercise or conversion by Joyce Meghan V of tradable shares of Guardant Health subject to Rule 16b-3
Kalia Kumud over three months ago via Macroaxis 
Sale by Kalia Kumud of 2000 shares of Guardant Health
Krognes Steve E over three months ago via Macroaxis 
Acquisition by Krognes Steve E of 11879 shares of Guardant Health subject to Rule 16b-3
Saia John G over three months ago via Macroaxis 
Acquisition by Saia John G of 30274 shares of Guardant Health subject to Rule 16b-3
Bell Michael Brian over three months ago via Macroaxis 
Acquisition by Bell Michael Brian of 454 shares of Guardant Health subject to Rule 16b-3
Freeman Chris over three months ago via Macroaxis 
Exercise or conversion by Freeman Chris of 4879 shares of Guardant Health subject to Rule 16b-3
Stanley Meresman over three months ago via Macroaxis 
Exercise or conversion by Stanley Meresman of 1814 shares of Guardant Health subject to Rule 16b-3
Bell Michael Brian over six months ago via Macroaxis 
Acquisition by Bell Michael Brian of 19727 shares of Guardant Health subject to Rule 16b-3
Helmy Eltoukhy over six months ago via Macroaxis 
Purchase by Helmy Eltoukhy of 37591 shares of Guardant Health
Kalia Kumud over six months ago via Macroaxis 
Guardant Health exotic insider transaction detected

Guardant Health Technical and Predictive Indicators

Guardant Health Forecast Models

Guardant Health time-series forecasting models is one of many Guardant Health's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Guardant Health's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Guardant Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Guardant Health prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Guardant shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Guardant Health. By using and applying Guardant Stock analysis, traders can create a robust methodology for identifying Guardant entry and exit points for their positions.
Last ReportedProjected for 2022
Operating Margin(102.25) (110.33) 
EBITDA Margin(97.85) (105.57) 
Gross Margin 67.11  56.59 
Profit Margin(79.66) (85.95) 

Current Guardant Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Guardant analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Guardant analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
167.33Buy9Odds
Guardant Health current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Guardant analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Guardant stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Guardant Health, talking to its executives and customers, or listening to Guardant conference calls.
Guardant Analyst Advice Details

Guardant Stock Analysis Indicators

Guardant Health stock analysis indicators help investors evaluate how Guardant Health stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Guardant Health shares will generate the highest return on investment. By understating and applying Guardant Health stock analysis, traders can identify Guardant Health position entry and exit signals to maximize returns.
Begin Period Cash Flow832977000.00
Logo U R LimglogosUSGH.png
Common Stock Shares Outstanding101420000.00
Total Stockholder Equity645005000.00
DescriptionGuardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advance
Total Cashflows From Investing Activities-63155000.00
Tax Provision300000.00
Property Plant And Equipment Net313904000.00
Retained Earnings-1007825000.00
Cash And Short Term Investments932748000.00
Retained Earnings Total Equity-1007825000.00
Cash492202000.00
CodeGH
Accounts Payable17580000.00
Net Debt881528000.00
50 Day M A49.8128
Total Current Liabilities194687000.00
Currency CodeUSD
Other Operating Expenses784654000.00
Non Current Assets Total1090373000.00
Common Stock Total Equity1000.00
Non Currrent Assets Other60938000.00
Please check Risk vs Return Analysis. Note that the Guardant Health information on this page should be used as a complementary analysis to other Guardant Health's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.

Complementary Tools for Guardant Stock analysis

When running Guardant Health price analysis, check to measure Guardant Health's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Guardant Health is operating at the current time. Most of Guardant Health's value examination focuses on studying past and present price action to predict the probability of Guardant Health's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Guardant Health's price. Additionally, you may evaluate how the addition of Guardant Health to your portfolios can decrease your overall portfolio volatility.
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Is Guardant Health's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Guardant Health. If investors know Guardant will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Guardant Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
5.4 B
Quarterly Revenue Growth YOY
0.24
Return On Assets
(0.16) 
Return On Equity
(1.25) 
The market value of Guardant Health is measured differently than its book value, which is the value of Guardant that is recorded on the company's balance sheet. Investors also form their own opinion of Guardant Health's value that differs from its market value or its book value, called intrinsic value, which is Guardant Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Guardant Health's market value can be influenced by many factors that don't directly affect Guardant Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Guardant Health's value and its price as these two are different measures arrived at by different means. Investors typically determine Guardant Health value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Guardant Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.